drugset / Trial / NCT03672851
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
Phase 1
Terminated
2 enrolled
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia in a dose-escalation way.
Timeline
- Start
- 2019-04-17
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
Outcome
Outcome not reported
Stopped: “adverse effect”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD123 CAR-T cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | anti-CD123 CAR-T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 300 mg/m2 | Intravenous |